<div id="readability-page-1"><div> <div> , /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to ImmunityBio, Inc. (&#34;ImmunityBio&#34; or the &#34;Company&#34;) (NASDAQ: IBRX) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN IMMUNITYBIO, INC. (IBRX), CLICK HERE BEFORE MAY 26, 2026 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. What Is The Lawsuit About? The complaint filed alleges that, between January 19, 2026 and March 24, 2026, Defendants failed to disclose to investors that: (1) Defendant Soon-Shiong materially overstated Anktiva's capabilities; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. The Law Offices of Frank R. Cruz, Email us at: [email protected] Call us at: 310-914-5007 Visit our website at: www.frankcruzlaw.com Follow us for updates on Twitter: twitter.com/FRC_LAW. If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. SOURCE The Law Offices of Frank R. Cruz, Los Angeles <img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE5Jk5ld3NJdGVtSWQ9TEE2MzI4OCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTkxNTQ3UFJfTkVXU19VU1BSX19fX19MQTYzMjg4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE5Jk5ld3NJdGVtSWQ9TEE2MzI4OCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTkxNTQ3UFJfTkVXU19VU1BSX19fX19MQTYzMjg4"/></div> </div></div>

IBRX

LABU

SBIO

Investors who suffered losses in ImmunityBio, Inc. (NASDAQ: IBRX) have the opportunity to lead a securities fraud class action lawsuit. The complaint alleges that the company misled investors about Anktiva's capabilities between January 19, 2026, and March 24, 2026. Interested parties must act before May 26, 2026, to participate.

prnewswire

ImmunityBio

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

15:47 ETImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit